Log in to search using one of your social media accounts:


European Commission grants orphan drug status to Apogenix ’s asunercept for MDS

German biopharmaceutical company Apogenix ’s asunercept (APG101) has received orphan drug designation from the European Commission (EC) to treat patients with myelodysplastic syndromes (MDS).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Germany Health | Grants | Myelodysplastic Syndrome | Pharmaceuticals